Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately 540 million ordinary shares in Haleon, one ... Read More
FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc's (LSE/NYSE: GSK) AREXVY, marking it as the first adjuvanted ... Read More
GSK acquires Elsie Biotechnologies for up to $50m to enhance oligonucleotide therapeutics
GSK plc (LSE/NYSE: GSK), a global healthcare leader, has completed the acquisition of Elsie Biotechnologies, a private biotechnology company based in San Diego, for a ... Read More
GSK reveals significant Shingrix vaccine efficacy in ZOSTER-049 trial
GSK plc announced the results of the ZOSTER-049 phase III long-term follow-up trial, showcasing that the Shingrix (Recombinant Zoster Vaccine or RZV) maintains high efficacy ... Read More
GSK advances in Hepatitis B cure with FDA’s fast track for bepirovirsen
In a significant development for the treatment of chronic hepatitis B (CHB), GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration ... Read More
GSK seeks to extend shingles vaccine Shingrix to younger at-risk adults in China
GSK plc (LSE/NYSE: GSK) has reached a pivotal milestone in the prevention of shingles (herpes zoster) in China, with the Center for Drug Evaluation (CDE) ... Read More
GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma
GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in the treatment of relapsed or refractory multiple ... Read More
EC grants approval for GSK’s Omjjara for treatment of myelofibrosis patients with anaemia
In a landmark decision, the European Commission has approved GSK plc's Omjjara (momelotinib), introducing a revolutionary treatment for adult myelofibrosis patients suffering from moderate to ... Read More
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership with GSK, to evaluate the potential of ... Read More
GSK to acquire Aiolos Bio to expand respiratory treatment portfolio
GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focusing on ... Read More